Kura Oncology (KURA) Leerink Global Healthcare Conference 2026 summary

Commercial and financial highlights

• KOMZIFTI (ziftomenib) launched successfully, with $2.1 million in initial revenue and rapid market access, achieving 84% policy coverage within three months.

• Step edits favoring KOMZIFTI over competitors are being implemented by some payers, supporting market leadership ambitions.

• The relapsed refractory NPM1 mutant AML market is estimated at $350–$400 million annually, with ambitions to capture majority share and expand into the much larger frontline setting.

• Strong cash position of $667 million, plus $180 million in anticipated milestones, supports ongoing development and commercial plans through key phase III readouts.

• Quarter-over-quarter sales growth and market leadership in NPM1 mutant AML are targeted for the year.

Pipeline and clinical development

• Ziftomenib is being advanced in multiple combinations and settings, including frontline AML (KOMET-017), solid tumors, and GIST, with key data readouts expected in 2028 for frontline studies.

• Three combination datasets for ziftomenib are expected this year: 7+3 in newly diagnosed AML, Ven/Aza in relapsed refractory NPM1, and gilteritinib in relapsed refractory NPM1 FLT3 mutant AML.

• Early data show high response rates (70–80%) for ziftomenib plus Ven/Aza in patients not previously treated with venetoclax.

• GIST studies are ongoing, with dose escalation data expected next year and potential for expansion into earlier lines of therapy.

• A next-generation menin inhibitor is in discovery for solid tumors, and a non-oncology menin inhibitor program is advancing toward clinical entry in type 1 diabetes in the first half of next year.

Farnesyltransferase inhibitor (FTI) program

• Darlifarnib targets resistance mechanisms in solid tumors, with ongoing studies in renal cell carcinoma (RCC) and KRAS G12C mutated cancers.

• Upcoming data will include dose escalation and expansion in RCC, and first adagrasib combination data in heavily pre-treated patients with non-small cell lung, pancreatic, and colorectal cancers.

• The FTI opportunity is estimated at 200,000 incident patients, with a focus on both independent and collaborative development strategies.

• Competitive landscape is evolving, with new entrants in China pursuing covalent FTIs, but confidence remains in the current approach.